Breakthrough in ALS Treatment: Novel Delivery System Shows Promise

A researcher at the University of Missouri has achieved a significant advancement in the fight against amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The research, led by Smita Saxena, demonstrates that a natural molecule, GM1, can effectively reach the brain when encapsulated within a tiny, fat-based bubble. Early laboratory tests indicate this approach improves ALS symptoms, potentially paving the way for human clinical trials.

Understanding ALS and the Challenges of Treatment

ALS is a progressive neurodegenerative disease that attacks motor neurons, leading to muscle weakness, speech difficulties, and eventual paralysis. The disease’s complexity stems from multiple breakdowns within the brain that worsen over time [1]. Previous attempts to treat ALS have been hampered by the blood-brain barrier, a protective layer that prevents many therapeutics from reaching the brain.

Overcoming the Blood-Brain Barrier with Talineuren

Saxena’s team collaborated with InnoMedica, a biopharmaceutical company in Switzerland, to utilize a delivery system called Talineuren. Talineuren consists of microscopic lipid bubbles containing GM1. This approach was inspired by previous successful human clinical trials where Talineuren was used to deliver GM1 to patients with Parkinson’s disease [1], [3].

Promising Results in Preclinical Studies

In studies involving mice with an ALS-causing mutation, the Talineuren-encapsulated GM1 successfully crossed the blood-brain barrier and improved the health of motor neurons, leading to improved movement [1]. Further research, detailed in a publication in Advanced Science, reveals that Talineuren intersects with both mitochondrial and synaptic pathways to alleviate ALS pathology [2]. Specifically, the therapy demonstrated the following benefits in animal models:

• Increased GM1 levels in the brain compared to administering GM1 alone [3].
• Restoration of key mitochondrial functions in human patient-derived motor neurons [3].
• Improved motor function and extended median survival in ALS mouse models [3].
• Positive effects on multiple disease mechanisms, including mitochondrial stress, endoplasmic reticulum stress, synaptic integrity, inflammation, and toxic protein aggregates [3].

Future Directions and Clinical Trials

Researchers are optimistic that if clinical trials confirm the therapy’s effectiveness, it could be administered to younger individuals who have inherited the ALS-causing mutation, potentially preventing the onset of symptoms. Notably, Talineuren has already shown a strong safety profile in clinical trials for Parkinson’s disease [1]. The University of Missouri’s NextGen Precision Health building will be instrumental in facilitating the translation of this research into human clinical trials, aiming to improve the quality of life for individuals affected by ALS both in Missouri and worldwide [1].

The University of Missouri Healthcare also operates an ALS Treatment Center in Columbia, Missouri, providing specialized care for those living with the disease [4].